Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes
necessary for cancer cell growth. Drugs used in chemotherapy such as flavopiridol use
different ways to stop cancer cells from dividing so they stop growing or die. Combining
imatinib mesylate with flavopiridol may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of flavopiridol and
imatinib mesylate in treating patients with hematologic cancer.